Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Agenus stock in Canada | $4.26

Own Agenus shares in just a few minutes.

Agenus Inc
-$0.07 (-1.33%)

Agenus is a biotechnology business based in the US. Agenus stocks (AGEN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.55 – an increase of 6.23% over the previous week. Agenus employs 359 staff and has a trailing 12-month revenue of around $84.8 million.

How to buy Agenus stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: AGEN in this case.
  5. Research Agenus stocks. The platform should provide the latest information available.
  6. Buy your Agenus stocks. It's that simple.

How has Coronavirus impacted Agenus's stock price?

Since the stock market crash in March caused by coronavirus, Agenus's stock price has had significant positive movement.

Its last market close was $4.26, which is 17.37% up on its pre-crash value of $3.52 and 134.07% up on the lowest point reached during the March crash when the stocks fell as low as $1.82.

If you had bought $1,000 worth of Agenus stocks at the start of February 2020, those stocks would have been worth $540.76 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,157.61.

Agenus stock price

Use our graph to track the performance of AGEN stocks over time.

Agenus stocks at a glance

Information last updated 2021-07-30.
Latest market close$4.26
52-week range$2.5 - $5.79
50-day moving average $5.3862
200-day moving average $4.007
Wall St. target price$9
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.906

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Agenus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Agenus price performance over time

Historical closes compared with the last close of $4.26

1 month (2021-06-30) -22.40%
3 months (2021-04-30) 37.86%

Agenus financials

Revenue TTM USD$84.8 million
Gross profit TTM USD$-56,796,000
Return on assets TTM -38.13%
Return on equity TTM 0%
Profit margin -224.06%
Book value $-1.145
Market capitalisation USD$1.2 billion

TTM: trailing 12 months

How to short and sell Agenus stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "AGEN.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 22.6 million Agenus stocks held short by investors – that's known as Agenus's "short interest". This figure is 13.1% down from 26.0 million last month.

There are a few different ways that this level of interest in shorting Agenus stocks can be evaluated.

Agenus's "short interest ratio" (SIR)

Agenus's "short interest ratio" (SIR) is the quantity of Agenus stocks currently shorted divided by the average quantity of Agenus stocks traded daily (recently around 3.6 million). Agenus's SIR currently stands at 6.32. In other words for every 100,000 Agenus stocks traded daily on the market, roughly 6320 stocks are currently held short.

However Agenus's short interest can also be evaluated against the total number of Agenus stocks, or, against the total number of tradable Agenus stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Agenus's short interest could be expressed as 0.1% of the outstanding stocks (for every 100,000 Agenus stocks in existence, roughly 100 stocks are currently held short) or 0.1261% of the tradable stocks (for every 100,000 tradable Agenus stocks, roughly 126 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Agenus.

Find out more about how you can short Agenus stock.

Agenus stock dividends

We're not expecting Agenus to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have Agenus stocks ever split?

Agenus stocks were split on a 1:6 basis on 3 October 2011. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Agenus stocks – just the quantity. However, indirectly, the new 500% higher stock price could have impacted the market appetite for Agenus stocks which in turn could have impacted Agenus's stock price.

Agenus stock price volatility

Over the last 12 months, Agenus's stocks have ranged in value from as little as $2.5 up to $5.79. A popular way to gauge a stock's volatility is its "beta".

AGEN.US volatility(beta: 1.37)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agenus's is 1.3678. This would suggest that Agenus's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Agenus overview

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Stocks similar to Agenus

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site